Teruo Inoue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Teruo Inoue has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Koichi Node
Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, 5-1-1 Nabeshima, Saga 849-8501, Japan
19 shared publications- Koichi Node
Department of Cardiovascular Medicine, Saga University, Saga, Japan
10 shared publications Toshihiko Uchida
8 shared publicationsYutaka Hikichi
7 shared publicationsHiroshi Komoda
6 shared publicationsKan Takayanagi
5 shared publications
Latest Publications
- 31 March 2018
- Published by Japan Society for Vascular Failure in Vascular Failure
- Vol. 2  (1) , 53-58
Microvascular endothelial function in patients with obstructive sleep apnea syndrome
Background: Obstructive sleep apnea syndrome (OSAS) is a novel risk factor for cardiovascular disease (CVD) and thought to be associated with endothelial dysfunction. Although many reports have demonstrated endothelial dysfunction of large conduit artery by flow-mediated dilatation in patients with OSAS, only a few reports have assessed microvascular endothelial function in OSAS patients. In this study, we investigated microvascular endothelial function by reactive hyperemia-peripheral arterial tonometry (RH-PAT) in patients with OSAS and assessed the effects of continuous positive airway pressure (CPAP) treatment on microvascular endothelial function. Methods: Twelve male patients with OSAS (51±13 yrs, body mass index [BMI]: 27.6±7.1 kg/m2, apnea hypopnea index [AHI]: 44±18/hr) and 12 male patients with CVD (54±13 yrs, BMI: 25.5±3.0 kg/m2) underwent an endothelial function test by RH-PAT using Endo-PAT 2000 before and 12 months after induction of CPAP treatment. Results: The baseline reactive hyperemia index (RHI) in patients with OSAS was similar to that in patients with CAD (1.78±0.48 vs 1.79±0.36, P=0.878). In patients with OSAS, the RHI increased 12 months after CPAP treatment (to 2.32±0.40; P=0.003). The change in RHI from baseline after CPAP treatment tended to have a negative correlation with the baseline 3% oxygen desaturation index (3% ODI) (R=-0.526, P=0.079) and was correlated negatively with the baseline AHI (R=-0.607, P=0.036). Conclusion: Microvascular endothelial function is impaired in patients with OSAS, but improves after CPAP treatment. In addition, the improvement of microvascular endothelial function through CPAP treatment was driven by mainly patients with mild to moderate OSAS at baseline.
- 31 March 2018
- Published by Japan Society for Vascular Failure in Vascular Failure
- Vol. 2  (1) , 53-58
Microvascular endothelial function in patients with obstructive sleep apnea syndrome
Background: Obstructive sleep apnea syndrome (OSAS) is a novel risk factor for cardiovascular disease (CVD) and thought to be associated with endothelial dysfunction. Although many reports have demonstrated endothelial dysfunction of large conduit artery by flow-mediated dilatation in patients with OSAS, only a few reports have assessed microvascular endothelial function in OSAS patients. In this study, we investigated microvascular endothelial function by reactive hyperemia-peripheral arterial tonometry (RH-PAT) in patients with OSAS and assessed the effects of continuous positive airway pressure (CPAP) treatment on microvascular endothelial function. Methods: Twelve male patients with OSAS (51±13 yrs, body mass index [BMI]: 27.6±7.1 kg/m2, apnea hypopnea index [AHI]: 44±18/hr) and 12 male patients with CVD (54±13 yrs, BMI: 25.5±3.0 kg/m2) underwent an endothelial function test by RH-PAT using Endo-PAT 2000 before and 12 months after induction of CPAP treatment. Results: The baseline reactive hyperemia index (RHI) in patients with OSAS was similar to that in patients with CAD (1.78±0.48 vs 1.79±0.36, P=0.878). In patients with OSAS, the RHI increased 12 months after CPAP treatment (to 2.32±0.40; P=0.003). The change in RHI from baseline after CPAP treatment tended to have a negative correlation with the baseline 3% oxygen desaturation index (3% ODI) (R=-0.526, P=0.079) and was correlated negatively with the baseline AHI (R=-0.607, P=0.036). Conclusion: Microvascular endothelial function is impaired in patients with OSAS, but improves after CPAP treatment. In addition, the improvement of microvascular endothelial function through CPAP treatment was driven by mainly patients with mild to moderate OSAS at baseline.
- 20 June 2016
- p. 321-6
[Inflammatory biomarkers].
- 1 May 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 111  (9) , 1246-1252
Evaluation of Serial Changes in Tissue Characteristics During Statin-Induced Plaque Regression Using Virtual Histology-Intravascular Ultrasound Studies
- 1 May 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 111  (9) , 1246-1252
Evaluation of Serial Changes in Tissue Characteristics During Statin-Induced Plaque Regression Using Virtual Histology-Intravascular Ultrasound Studies
- 31 January 2012
- Published by Elsevier in Journal of Cardiology
- Vol. 59  (1) , 91-96
Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model
- 31 January 2012
- Published by Elsevier in Journal of Cardiology
- Vol. 59  (1) , 91-96
Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model
- 15 November 2010
- Published by Elsevier in International Journal of Cardiology
- Vol. 156  (2) , 144-147
Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure
- 15 November 2010
- Published by Elsevier in International Journal of Cardiology
- Vol. 156  (2) , 144-147
Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure
- 30 April 2009
- Published by Elsevier in Journal of Cardiology
- Vol. 53  (2) , 232-239
Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease
- 30 April 2009
- Published by Elsevier in Journal of Cardiology
- Vol. 53  (2) , 232-239
Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease
- 31 January 2009
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 83  (1) , 77-82
Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance
- 31 January 2009
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 83  (1) , 77-82
Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance
- Open Access
- 28 January 2009
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 8  (1) , 5
Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
Background: The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity impairment. Methods: Metabolic and inflammatory parameters were analyzed from stored frozen serum samples obtained from 108 patients enrolled in the Bezafibrate Infarction Prevention (BIP) Study. They presented with New York Heart Association (NYHA) functional class III, comprising 58 patients in the bezafibrate group and 50 in the placebo groups, and completed a 2-year prospective, double-blind, placebo-controlled follow-up. Results: During follow-up ProBNP level did not change significantly in the placebo group, whereas it increased slightly in the bezafibrate group, which was older and with lower baseline ProBNP values. No significant differences between the groups were found for ProBNP levels after 2 year of follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and baseline ProBNP level- showed that bezafibrate was not associated with longitudinal ProBNP changes during the follow-up period (p = 0.3). Conclusion: Long-term treatment by bezafibrate was not associated with longitudinal ProBNP changes in patients with pre-existing CAD and advanced functional capacity impairment.
- 28 January 2009
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 8  (1) , 5
Open AccessLong-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
Background: The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity impairment. Methods: Metabolic and inflammatory parameters were analyzed from stored frozen serum samples obtained from 108 patients enrolled in the Bezafibrate Infarction Prevention (BIP) Study. They presented with New York Heart Association (NYHA) functional class III, comprising 58 patients in the bezafibrate group and 50 in the placebo groups, and completed a 2-year prospective, double-blind, placebo-controlled follow-up. Results: During follow-up ProBNP level did not change significantly in the placebo group, whereas it increased slightly in the bezafibrate group, which was older and with lower baseline ProBNP values. No significant differences between the groups were found for ProBNP levels after 2 year of follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and baseline ProBNP level- showed that bezafibrate was not associated with longitudinal ProBNP changes during the follow-up period (p = 0.3). Conclusion: Long-term treatment by bezafibrate was not associated with longitudinal ProBNP changes in patients with pre-existing CAD and advanced functional capacity impairment.
- Open Access
- 1 January 2009
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 73  (4) , 615-621
Molecular Basis of Restenosis and Novel Issues of Drug-Eluting Stents
Restenosis after stent deployment is an overreaction of the wound healing response after vascular injury, and is characterized by the sequence of inflammation, granulation, extracellular matrix remodeling, and smooth muscle cell (SMC) proliferation and migration. In contrast, reendothelialization of at least part of the injured vessel surface, which is essential in the wound healing process, may occur at the site of stenting. Recent advances in drug-eluting stents (DES) have substantially reduced restenosis, but do not contribute to improve long-term prognosis, compared with bare metal stents (BMS). One of the reasons may be that reendothelialization is impaired after DES stenting. Regenerated endothelial cells and proliferated SMCs in the neointima are both in part derived from their progenitor cells, which are mobilized from bone marrow to injured vessel sites and differentiate into both vascular endothelial cells and SMCs. DES inhibits mobilization and differentiation of endothelial and smooth muscle progenitor cells, and thus not only inhibits restenosis but also impairs reendothelialization, which may lead to late stent thrombosis. To improve long-term prognosis in the DES era, adjunctive medical treatments inducing early reendothelialization, but inhibiting SMC proliferation, would be required. (Circ J 2009; 73: 615 - 621)
- 1 January 2009
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 73  (4) , 615-621
Open AccessMolecular Basis of Restenosis and Novel Issues of Drug-Eluting Stents
Restenosis after stent deployment is an overreaction of the wound healing response after vascular injury, and is characterized by the sequence of inflammation, granulation, extracellular matrix remodeling, and smooth muscle cell (SMC) proliferation and migration. In contrast, reendothelialization of at least part of the injured vessel surface, which is essential in the wound healing process, may occur at the site of stenting. Recent advances in drug-eluting stents (DES) have substantially reduced restenosis, but do not contribute to improve long-term prognosis, compared with bare metal stents (BMS). One of the reasons may be that reendothelialization is impaired after DES stenting. Regenerated endothelial cells and proliferated SMCs in the neointima are both in part derived from their progenitor cells, which are mobilized from bone marrow to injured vessel sites and differentiate into both vascular endothelial cells and SMCs. DES inhibits mobilization and differentiation of endothelial and smooth muscle progenitor cells, and thus not only inhibits restenosis but also impairs reendothelialization, which may lead to late stent thrombosis. To improve long-term prognosis in the DES era, adjunctive medical treatments inducing early reendothelialization, but inhibiting SMC proliferation, would be required. (Circ J 2009; 73: 615 - 621)
- Open Access
- 1 January 2009
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 8  (1) , 23
Postprandial hyperglycemia as an etiological factor in vascular failure
Postprandial hyperglycemia is characterized by hyperglycemic spikes that induce endothelial dysfunction, inflammatory reactions and oxidative stress, which may lead to progression of atherosclerosis and occurrence of cardiovascular events. Emerging data indicate that postprandial hyperglycemia or even impaired glucose tolerance may predispose to progression of atherosclerosis and cardiovascular events. There is evidence that postprandial hyperglycemia, but not fasting hyperglycemia, independently predicts the occurrence of cardiovascular events. We proposed a concept of 'vascular failure' as a comprehensive syndrome of vascular dysfunction extending from risk factors to advanced atherosclerotic disease. Postprandial hyperglycemia is therefore one of the very important pathophysiological states contributing to vascular failure. Accordingly, controlling postprandial hyperglycemia should be the focus of future clinical investigation as a potential target for preventing vascular failure.
- 1 January 2009
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 8  (1) , 23
Open AccessPostprandial hyperglycemia as an etiological factor in vascular failure
Postprandial hyperglycemia is characterized by hyperglycemic spikes that induce endothelial dysfunction, inflammatory reactions and oxidative stress, which may lead to progression of atherosclerosis and occurrence of cardiovascular events. Emerging data indicate that postprandial hyperglycemia or even impaired glucose tolerance may predispose to progression of atherosclerosis and cardiovascular events. There is evidence that postprandial hyperglycemia, but not fasting hyperglycemia, independently predicts the occurrence of cardiovascular events. We proposed a concept of 'vascular failure' as a comprehensive syndrome of vascular dysfunction extending from risk factors to advanced atherosclerotic disease. Postprandial hyperglycemia is therefore one of the very important pathophysiological states contributing to vascular failure. Accordingly, controlling postprandial hyperglycemia should be the focus of future clinical investigation as a potential target for preventing vascular failure.